Intellia board member Caroline Dorsa to resign effective June 15, 2023

Intellia Therapeutics, Inc.

Caroline Dorsa resigned from Intellia board and all committees effective June 15, 2023.
She served as Audit Committee Chair and on the Compensation and Talent Development Committee.
Resignation follows her appointment as chair of Biogen's board; no disagreement with Intellia.
Company thanked Dorsa for her long, dedicated service.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Caroline Dorsa

Director

NTLA · Intellia Therapeutics, Inc.

Effective: 2023-06-15
Filed: March 24, 2023, 7:59 PM ET

On March 23, 2023, Caroline Dorsa notified Intellia Therapeutics, Inc. (the “Company”) of her intent to resign from the Board of Directors (the “Board”) of the Company and its committees, effective June 15, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Caroline Dorsa resigned as Director at Intellia Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On March 23, 2023, Caroline Dorsa notified Intellia Therapeutics, Inc. (the “Company”) of her intent to resign from the Board of Directors (the “Board”) of the Company and its committees, effective June 15, 2023.

View on SEC.gov

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-078511

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.